
Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class.Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therapies-and-patient-outcomes-with-david-rubin-md
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Joint Ventures: EULAR 2026 Congress Preview

Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus

Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier

Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2
Free AI-powered recaps of HCPLive Podcasts and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.